Introduction
Acute myeloid leukemia (AML) patients who fail to achieve complete remission (CR) or relapse after first-line therapy have a very poor prognosis and it is generally accepted that few cures can be achieved at this stage using chemotherapy alone. 1 The principle behind timed sequential chemotherapy (TSC) is to recruit leukemic cells in the cell cycle using a first sequence of chemotherapy and to administer the second sequence, using cycle active drugs, at the presumed time of peak cell recruitment induced by the first sequence to maximize leukemic cell kill by cytotoxic agents. 2 This approach has been shown clinically useful both as first-line therapy in newly diagnosed patients, 3 and in patients relapsing after conventional daunorubicin-cytarabine treatments. 4 By comparison with initially described TSC regimen, which included daunorubicin and cytarabine in the first sequence and cytarabine alone in the second sequence, the EMA 86 regimen introduced mitoxantrone instead of daunorubicin in the first sequence and added etoposide to cytarabine in the second sequence. 5 This regimen has shown high efficacy in a cohort of 133 patients with previously treated AML, inducing a CR rate of 44% in previously refractory and in 76% in late first relapse patients. 6 Granulocyte-macrophage colony-stimulating factor (GM-CSF), has been shown to induce proliferation of AML cells in vitro [7] [8] [9] [10] [11] [12] [13] [14] and to increase their in vitro sensitivity to cycle-active drugs such as cytarabine, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] raising hopes of increasing efficacy of chemotherapy in AML. One study showed an increase in survival of leukemic mice treated with cytarabine and GM-CSF compared to cytarabine alone. 29 Initial non-randomized studies associating GM-CSF with cytarabine and daunorubicin showed the feasibility of this approach. 30, 31 Although induction treatment with a standard daunorubicin/cytarabine combination associated with GM-CSF administration did not provide any clinical benefit, 32 TSC seemed ideally suited to be associated with GM-CSF therapy since its efficacy is believed to be directly related to the increase in S phase cells before the second sequence of chemotherapy. 33 However, a limitation of this association was the potential increase of aplasia duration if normal stem cells were also recruited into the cell cycle. After a pilot study (EMA90 regimen), showing the feasibility of administering GM-CSF between the two sequences of EMA86 regimen without increasing hematological toxicity, 34 a phase III randomized double-blind study of the administration of GM-CSF in association with EMA TSC was undertaken (EMA91 study). The results of this study are reported here.
Patients and methods

Patients
All patients had AML defined according to standard FrenchAmerican-British (FAB) cytological and cytochemical criteria. [35] [36] [37] Patients were either nonresponsive to initial chemotherapy or in first or subsequent relapse. Only patients aged less than 65 years with a performance status of 2 or less and no grade Ͼ2 organ failure according to the World Health Organization (WHO) grading system 38 could enter the study, except if failure was related to the leukemia itself.
Nonresponse to chemotherapy was defined as the absence of complete remission after two courses of intensive anthracycline and cytarabine containing chemotherapy or after only one course provided that bone marrow evaluation on or after day 28 showed persistence of more than 50% blasts. Previous refractoriness was defined, according to Hiddeman et al, 39 as (1) nonresponse, (2) early first relapse, occurring after a first CR of less than 6 months duration or while the patient was still on therapy, and (3) second and subsequent relapses. Late first relapse was defined as first relapse occurring while off therapy after a first CR of 6 months duration or more. All patients had to give written informed consent according to national policy.
EMA91 regimen
The chemotherapy regimen has already been described in detail. 5 Induction included a first sequence of chemotherapy combining mitoxantrone, 12 mg/m 
Evaluation of therapy
CR and relapse were defined according to the CALGB criteria. 40 Treatment failures were classified according to Preisler, 41 as nonresponse (NR), including all patients with proven blastic regrowth following chemotherapy even if they died before blood count recovery, and other failures (OF) corresponding to patients who died while nonblastic of presumably chemotherapy-related toxicity. Severity of treatmentrelated toxicity was graded according to the WHO criteria. 38 
Cell cycle analyses
Patients had bone marrow sampling for cytologic examination and cell cycle studies on day 0, day 4 (before administration of GM-CSF or placebo) and day 8 (before initiation of the second sequence of chemotherapy).
Cell cycle studies were carried out through a standard method using the incorporation of bromodeoxyuridine (BrdU) in bone marrow cells isolated in Ficoll and detection of Sphase cells having incorporated BrdU using an indirect immunofluorescence method on cytospin slides. 42 
Statistical analysis
The primary endpoints of this study were the percent of CR and the proportion of patients remaining progression-free at 18 months in both treatment groups. The study was sized to detect a difference of 25% in CR rate or of 20% in the proportion of patients remaining progression-free at 18 months between the two arms (␣ = 0.05) with a statistical power of 90% using two-sided tests.
Complete remission rates by treatment group (GM-CSF or placebo) were compared using chi-square and 95% confidence intervals (CI) on proportions of CR, NR and OF patients were calculated using the exact binomial formula. Survival, disease-free survival (DFS) and progression-free probabilities were calculated using the Kaplan-Meier product-limit estimate method and their 95% symmetrical CI limit was calculated according to Greenwood's method. Survival curves were compared using the log-rank test. In addition to treatment group, the following parameters were analyzed for potential prognostic significance for CR achievement, time to progression, DFS and overall survival: age, sex, previous therapy, indication for EMA regimen (refractoriness vs late first relapse, and primary AML vs secondary AML and AML following a previous MDS), WHO performance status, initial hepatosplenomegaly or other extramedullary involvement, fever and hemorrhages, initial blood counts, percent of bone marrow blasts, FAB morphologic subtype, bilirubinemia, serum liver enzymes and lactate dehydrogenase (LDH) levels. In the analysis, quantitative variables were treated as dichotomous with cut off points at the approximate median value, or were compared using t-test. Prognostic factors for CR were studied using stepwise multiple logistic regression and prognostic factors for DFS and overall survival were studied using stepwise Cox's proportional hazard model. All variables that were statistically (two-tailed P Ͻ 0.1) predictive for CR achievement or survival and their interactions were proposed for entry in the stepwise multivariate model for prediction of the same endpoint. Goodness of fit of the models was tested using the likelihood ratio statistics. All computations were made using SAS software version 6.12 for Windows 95.
Results
Patient population
One hundred and ninety-six patients from the 16 participating centers were randomized in the study. Four patients, all of them in the placebo group, did not receive the first day of chemotherapy, because of abrupt death (one patient), patient refusal (one patient), or physician's decision to perform direct allogeneic transplantation (two patients): these patients were excluded from analysis. The remaining 192 patients, 95 randomized in the GM-CSF group and 97 in the placebo group, received at least 1 day of chemotherapy and were analyzed. Main initial characteristics of patients according to their treatment group are indicated in Table 1 , showing no major imbalance between the two groups of patients, except for an excess of female patients in the GM-CSF group compared to the placebo group (P = 0.009). Not shown in Table 1 , patients in the GM-CSF group also had on average higher serum glutamateoxaloacetate transaminase levels than patients who received placebo (P = 0.03). Four patients in the GM-CSF group and six in the placebo group were relapsing after myeloablative therapy followed by autologous stem cell transplantation.
Treatment effectively received
All patients received the full dose of all three chemotherapeutic agents involved in the induction course except for patients who died during the initial 10 days of induction. Most patients in CR were scheduled to receive the protocol maintenance courses of chemotherapy. Fourteen patients, nine in the GM-CSF group and five in the placebo group, received autologous stem cell transplantation while 18, nine in each treatment group, underwent allogeneic transplantation.
Efficacy of therapy
Results of induction regimen according to treatment group and stage of AML at randomisation are reported in Table 2 . Overall, 62 patients in the GM-CSF group (65%, CI: 56-75%) and 57 in the placebo group (59%, CI: 49-69%) achieved CR after the course of induction, without significant difference between the two groups (P = 0.35). Complete remission rates in the subgroups of refractory and late first relapse patients were 51% (CI: 38-64%) and 89% (CI: 79-99%) respectively in the GM-CSF group and 46% (CI: 33-58%) and 81% (CI: 68-93%) respectively in the placebo group. Five percent of patients died from toxicity during induction in the GM-CSF arm compared to 8% in the placebo arm. In a multivariate analysis, WHO performance status at 0 (P = 0.04), high initial hemoglobin level (P = 0.01), absence of initial infectious disease (P = 0.002), and late first relapse AML (P = 0.0001) were predictive factors for CR achievement.
At a median follow-up of 9 months, 40 patients in the GM-CSF group, who achieved a CR with induction therapy, have relapsed, four of them after autologous and two after allogeneic transplantation, while 44 in the placebo group have relapsed, one of them after autologous and six after allogeneic transplantation. There was a trend towards longer time to progression in the GM-CSF arm compared to the placebo arm: median time to progression was 154 days with 33% (CI: 23-42%) of patients remaining progression-free in the GM-CSF arm, while it was 115 days with 19% (CI: 11-27%) of patients remaining progression-free in the placebo arm (P = 0.08) (Figure 1a) . This difference was mainly due to longer time to an increase in time to progression in refractory patients receiving GM-CSF compared to patients in the same strata receiving placebo (P = 0.06, Figure 1b ) while time to progression in
Figure 2
Disease-free survival (a) and survival (b) in the whole cohort of patients according to randomization group. late first relapse patients appeared not to be affected by the administration of GM-CSF (Figure 1c) . Ten patients died while in complete remission in the GM-CSF group, three of them from late complication of induction chemotherapy, one following autologous and six following allogeneic transplantation. Comparatively in the placebo group, one patient died in early CR and two after allogeneic transplantation. Median disease-free survival and survival were 251 and 303 days, respectively, in the GM-CSF group, and 240 and 254 days, respectively, in the placebo group, without significant difference in disease-free survival and survival at 18 months between the treatment groups (P = 0.45 and 0.32, respectively) (Figure 2) .
In the multivariate analysis, late first relapse AML (P = 0.0001) and high initial hemoglobin level (P = 0.003) were predictive for longer time to progression at 18 months. Younger age (P = 0.02) and AML not secondary to a previous malignant disease or MDS (P = 0.008) were predictive factors for longer DFS at 18 months. Late first relapse AML (P = 0.0002), WHO performance status at 0 (P = 0.004), and low initial WBC count (P = 0.0002) were predictive for longer overall survival at 18 months.
Cell cycle analyses
Results of cell cycle analysis performed on days 0, 4 and 8 of induction chemotherapy in approximately 100 patients are reported in Table 3 , showing a slight increase in the percent of blast cells in S phase between day 4 and day 8 of induction therapy (ie during the administration of study drug) in patients receiving GM-CSF while there was a slight decrease over the same period in patients who received placebo (P = 0.006), indicating significant blast cell recruitment in the cell cycle by GM-CSF. This effect was noted in the absence of any increase in the white blood cell count, bone marrow cellularity or percent of blast cells in the bone marrow in any patient during GM-CSF administration. However, none of the cell cycle parameters, including recruitment of blast cells in the cell cycle between day 4 and day 8, appeared to be related to prognosis (CR achievement, time to progression, disease-free survival and survival) in the cohort of patients studied.
Toxicity of induction
All patients underwent severe hematologic toxicity, without any significant difference between the two treatment groups, with neutrophil recovery above 0.5 × 10 9 /l at a median of 38 days (range 7-82 days) from initiation of chemotherapy in the GM-CSF group and 37 days (range 29-66 days) in the placebo group. The last platelet transfusion occurred at a median of 32 days (range 19-70 days) and 32 days (range 21-126 days) and platelet recovery above 50 × 10 9 /l at a median of 48 days (range 28-109 days) and 45 days (range 29-134 days) in the GM-CSF and placebo groups, respectively. Severe adverse effects (WHO grade 3 or more) observed during induction in the two treatment groups are reported in Table 4 , showing no difference between the two groups. Infectious complications were the most frequent, followed by oral mucositis. No adverse effect appeared unequivocally related to the use of GM-CSF as opposed to placebo.
Discussion
Results presented here confirm the high initial anti-leukemic efficacy of the EMA regimen noted in previous studies from our group, despite treating more recently diagnosed patients who had probably received previously more intensive therapy than patients treated on EMA86 study. 6 EMA91 is, to our knowledge, the first randomized study of the administration of a growth factor only during chemotherapy in relapsed or refractory AML patients. This approach with growth factor aims at an enhancement of the antileukemic effect of chemo- Table 3 Results of cell cycle analysis by treatment group therapy by a recruitment of chemoresistant resting leukemic cells into sensitive phases of the cell cycle. In that setting, timed sequential chemotherapy, based on the observation that after initial intensive therapy leukemic cells can be recruited synchronously into the cell cycle, seems to be an attractive approach. Numerous randomised studies in AML were designed to take advantage of the potential sensitization of leukemic cells to cytotoxic agents by GM-CSF 32,43-47 or G-CSF. 48 However, these studies involved the administration of the growth factor not only during chemotherapy, but also for one 43 or two 44, 45, 47, 48 days preceding chemotherapy, or after chemotherapy, until recovery from aplasia. [43] [44] [45] [46] [47] The unique reported randomized study involving the administration of G-CSF during chemotherapy did not show any effect on relapse rate. 48 Two studies using GM-CSF in newly diagnosed AML 43, 46 and our present study using GM-CSF in relapsed or refractory AML showed a favorable effect on relapse rate. Noteworthy, in two of these three studies, GM-CSF administration was initiated either after day 1 of cytotoxic chemotherapy or at time of chemotherapy initiation. 46 This tends to confirm one early nonrandomized study 49 and a more recent randomized study 47 showing a possible deleterious effect of the administration of GM-CSF before chemotherapy in patients with florid AML. In these two studies, a decrease in CR rate, possibly related to gross stimulation of the leukemia by the growth factor, with an increase in blast cell count before initiation of chemotherapy possibly overwhelmed the benefit of blast cell sensitization by GM-CSF. 47, 49 Other studies testing GM-CSF during standard chemotherapy did not provide any clinical benefit in AML patients. 32, 44 In contrast, in one recent large randomized study addressing newly diagnosed patients, a major effect of GM-CSF to decrease relapse rate was noted. 46 The more striking effect of GM-CSF in this study compared to our could be related to treatment of newly diagnosed leukemia, which is less at risk of relapse than the previously treated patients addressed by our study, or to the timing of administration of GM-CSF. In Witz et al's study, 46 GM-CSF was administered concomitantly with cytotoxic drugs for 6 days vs only 1 day (day 8) in our study. This could be important since it has now been demonstrated that sensitization of leukemic cells to GM-CSF involves not only the recruitment of cells in the cell cycle prior to drug exposure, but also a more global stimulation of their metabolism, prob-ably allowing for better uptake and processing of cytarabine, 27, 28 and explaining sensitization to relatively non-cell cycle-dependent drugs such as intercalating agents. 18, 22 This other mechanism might require the concomitant presence of the growth factor and the cytotoxic drug. Furthermore, in the trial by Witz et al, 46 GM-CSF was also administered during chemotherapy-induced aplasia, which might have contributed to induce differentiation of the residual leukemic cells or their killing by the immune system. 50 However, the effect of administration of GM-CSF during aplasia remains controversial since it appeared to decrease CR rate in one randomized study, 47 possibly by stimulating residual leukemic cells.
The result of cell cycle studies in our trial seem to indicate that, indeed, leukemic cell recruitment in the cell cycle is not necessary for GM-CSF to sensitize leukemic cells to cytotoxic agents. However, methods for enumerating cells in S phase remain rather unprecise, particularly on day 8 of chemotherapy when only a few leukemic cells remain in a generally already hypocellular bone marrow, and one cannot eliminate the possibility of a small minority of relevant residual leukemic cells which would have been otherwise out of cell cycle being sensitized by the growth factor through their recruitment. To be noted is the lack of apparent leukemic cell recruitment by the first sequence of chemotherapy in the placebo group, which contrasts with the recruitment observed with older chemotherapy protocols using the same dose of cytarabine during the first sequence in association with daunorubicin instead of mitoxantrone. 33 The much longer serum and cellular half-life of mitoxantrone and its recognized increased cytotoxicity might have prevented detectable reappearance of leukemic cells in the S phase of the cell cycle before administration of the second sequence of chemotherapy on day 8. Finally, the lack of increase of the hematologic toxicity of chemotherapy by GM-CSF is in line with in vitro work showing sensitization of leukemic cells but not normal myeloid progenitors to antileukemic agents in the presence of myeloid growth factors. 51 Another explanation could relate to the fact that recovery from the approximately 5-week long aplasia induced by this chemotherapy regimen could originate from very immature stem cells not affected by GM-CSF.
Overall, this study confirms that GM-CSF might be useful to increase efficacy of chemotherapy in AML patients by a yet unclear mechanism, perhaps independent of direct recruitment of leukemic cells in the cell cycle. GM-CSF priming strategies as used in the above study may also benefit from a modulation of the cellular metabolism of antileukemic drugs. The fact that those effects are achieved without increased hematologic or extrahematologic toxicity of chemotherapy appears particularly interesting at a time when it seems that the increase in dose intensity of chemotherapy is close to reaching its limit, and certainly deserves further testing.
